open access

Vol 78, No 3 (2010)
Invited review paper
Published online: 2010-05-11
Submitted: 2013-02-22
Get Citation

Pneumonia in immunocompramised patients - general clinical view

Elżbieta Radzikowska
Pneumonol Alergol Pol 2010;78(3):236-243.

open access

Vol 78, No 3 (2010)
Published online: 2010-05-11
Submitted: 2013-02-22


Not available


Not available
Get Citation
About this article

Pneumonia in immunocompramised patients - general clinical view


Advances in Respiratory Medicine


Vol 78, No 3 (2010)

Article type

Invited review paper



Published online


Bibliographic record

Pneumonol Alergol Pol 2010;78(3):236-243.


Elżbieta Radzikowska

References (49)
  1. Woodhead M, Woodhead M, Blasi F, et al. Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases, Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases, European Respiratory Society, European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005; 26(6): 1138–1180.
  2. Deng JC, Standiford TJ. The systemic response to lung infection. Clin Chest Med. 2005; 26(1): 1–9.
  3. Fishman J. Infection in Solid-Organ Transplant Recipients. New England Journal of Medicine. 2007; 357(25): 2601–2614.
  4. Solé A, Salavert M. Fungal infections after lung transplantation. Transplantation Reviews. 2008; 22(2): 89–104.
  5. Jakóbisiak M. Główne komponenty i zasadnicze cechy odpowiedzi immunologicznej. W: Głąb J. Immunologia. Wydawnictwo Naukowe PWN, Warszawa 2008: 1–5.
  6. Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2004; 170(1): 22–48.
  7. Remund KF, Best M, Egan JJ. Infections relevant to lung transplantation. Proc Am Thorac Soc. 2009; 6(1): 94–100.
  8. Vandermarliere A, Van Audenhove A, Peetermans WE, et al. Mycobacterial infection after renal transplantation in a Western population. Transpl Infect Dis. 2003; 5(1): 9–15.
  9. Baddley JW, Stroud TP, Salzman D, et al. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis. 2001; 32(9): 1319–1324.
  10. Martínez-Girón R, Esteban JG, Ribas A, et al. Protozoa in respiratory pathology: a review. Eur Respir J. 2008; 32(5): 1354–1370.
  11. Chan KM, Allen SA. Infectious pulmonary complications in lung transplant recipients. Semin Respir Infect. 2002; 17(4): 291–302.
  12. Husain S, Chan KM, Palmer SM, et al. Bacteremia in lung transplant recipients in the current era. Am J Transplant. 2006; 6(12): 3000–3007.
  13. Anderson RL, Hiemstra PS, Ward C, et al. Antimicrobial peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Eur Respir J. 2008; 32(3): 670–677.
  14. Valentine VG, Bonvillain RW, Gupta MR, et al. Infections in lung allograft recipients: ganciclovir era. J Heart Lung Transplant. 2008; 27(5): 528–535.
  15. Puzio J, Kucewicz E, Sioła M, et al. [Atypical and opportunistic pulmonary infections after cardiac surgery]. Anestezjol Intens Ter. 2009; 41(1): 38–41.
  16. Kotsimbos TC, Snell GI, Levvey B, et al. Chlamydia pneumoniae serology in donors and recipients and the risk of bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2005; 79(3): 269–275.
  17. Milstone AP, Brumble LM, Barnes J, et al. A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir J. 2006; 28(1): 131–137.
  18. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med. 2006; 173(7): 707–717.
  19. Marti FM, Cullen MH, Roila F, et al. ESMO Guidelines Working Group. Management of febrile neutropenia: ESMO clinical recommendations. Ann Oncol. 2009; 20 Suppl 4: 166–169.
  20. Elting LS, Lu C, Escalante CP, et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol. 2008; 26(4): 606–611.
  21. Innes H, Lim SL, Hall A, et al. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer. 2008; 16(5): 485–491.
  22. Belperio JA, Weigt SS, Fishbein MC, et al. Chronic lung allograft rejection: mechanisms and therapy. Proc Am Thorac Soc. 2009; 6(1): 108–121.
  23. Bollée G, Sarfati C, Thiéry G, et al. Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest. 2007; 132(4): 1305–1310.
  24. Montoya JG, Giraldo LF, Efron B, et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis. 2001; 33(5): 629–640.
  25. Queipo JA, Broseta E, Santos M, et al. Mycobacterial infection in a series of 1261 renal transplant recipients. Clin Microbiol Infect. 2003; 9(6): 518–525.
  26. Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30 years. Arch Intern Med. 1999; 159(12): 1301–1309.
  27. Agustí C, Rañó A, Filella X, et al. Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response. Chest. 2003; 123(2): 488–498.
  28. Kim SH, Song KH, Choi SJ, et al. Diagnostic usefulness of a T-cell-based assay for extrapulmonary tuberculosis in immunocompromised patients. Am J Med. 2009; 122(2): 189–195.
  29. Shimizu Y, Sunaga N, Dobashi K, et al. Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study. BMC Infect Dis. 2009; 9: 47.
  30. Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore). 2005; 84(5): 291–302.
  31. Mohan AK, Coté TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis. 2004; 39(3): 295–299.
  32. Kucharz EJ, Korzeniewska-Koseła M, Kotulska A. Zalecenia postępowania w zapobieganiu i leczeniu gruźlicy u chorych leczonych antagonistami TNF-a. Reumatologia. 2008; 46: 51–54.
  33. Vidal L, Ben Dor I, Paul M, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrob Chemother. 2004; 54(1): 29–37.
  34. Inwazyjna aspergiloza w materiale autopsyjnym chorych leczonych w Instytucie Gruźlicy i Chorób Płuc w latach 1993–2000.
  35. Khalifah AP, Hachem RR, Chakinala MM, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med. 2004; 170(2): 181–187.
  36. Maschmeyer G, Beinert T, Buchheidt D, et al. Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Diagnosis and antimicrobial therapy of pulmonary infiltrates in febrile neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2003; 82 Suppl 2: S118–S126.
  37. Botha P, Archer L, Anderson RL, et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation. 2008; 85(5): 771–774.
  38. Glanville AR, Gencay M, Tamm M, et al. Chlamydia pneumoniae infection after lung transplantation. J Heart Lung Transplant. 2005; 24(2): 131–136.
  39. Thomas LD, Vilchez RA, White ZS, et al. A prospective longitudinal study of polyomavirus shedding in lung-transplant recipients. J Infect Dis. 2007; 195(3): 442–449.
  40. Morris A, Wei K, Afshar K, et al. Epidemiology and clinical significance of pneumocystis colonization. J Infect Dis. 2008; 197(1): 10–17.
  41. Pappas PG, Kauffman CA, Andes D, et al. Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48(5): 503–535.
  42. Pauw BDe, Walsh T, Donnelly J, et al. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases. 2008; 46(12): 1813–1821.
  43. Walsh TJ, Anaissie EJ, Denning DW, et al. Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46(3): 327–360.
  44. Utili R, Durante-Mangoni E, Basilico C, et al. Efficacy of caspofungin addition to trimethoprim-sulfamethoxazole treatment for severe pneumocystis pneumonia in solid organ transplant recipients. Transplantation. 2007; 84(6): 685–688.
  45. Glanville AR, Scott AIR, Morton JM, et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2005; 24(12): 2114–2119.
  46. Vos R, Vanaudenaerde BM, Geudens N, et al. Pseudomonal airway colonisation: risk factor for bronchiolitis obliterans syndrome after lung transplantation? Eur Respir J. 2008; 31(5): 1037–1045.
  47. Neurohr C, Huppmann P, Leuchte H, et al. Munich Lung Transplant Group. Human herpesvirus 6 in bronchalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome? Am J Transplant. 2005; 5(12): 2982–2991.
  48. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant. 2004; 4 Suppl 10: 160–163.
  49. Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant. 2008; 8(1): 9–14.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: